Biocon Biologics may close $3.34 billion Viatris deal in Q1

Out of $2 billion, $800 million will come through equity infusion from existing investors including parent Biocon and others such as Serum Institute of India, Abu Dhabi-based ADQ.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9vn87pf
via IFTTT